International Edition
Latest News
Health

Ozempic & Wegovy May Reverse Osteoarthritis Damage, Study Finds

Semaglutide Shows Promise in Reversing Osteoarthritis Damage Semaglutide, the active ingredient in medications like Ozempic and Wegovy, initially developed for type 2 diabetes and weight loss, is now showing potential as a treatment to reverse the debilitating tissue…

Ozempic & Wegovy May Reverse Osteoarthritis Damage, Study Finds

Semaglutide Shows Promise in Reversing Osteoarthritis Damage

Semaglutide, the active ingredient in medications like Ozempic and Wegovy, initially developed for type 2 diabetes and weight loss, is now showing potential as a treatment to reverse the debilitating tissue damage caused by osteoarthritis, the most common form of arthritis. Recent research suggests the drug’s benefits extend beyond weight reduction, impacting joint health at a fundamental, metabolic level.

Beyond Weight Loss: A New Mechanism of Action

For years, weight loss has been recognized as a key strategy for managing osteoarthritis, reducing stress on weight-bearing joints. However, new studies indicate semaglutide may protect joints through a weight-loss-independent mechanism. Researchers have discovered the drug reprograms the metabolism of cells responsible for synthesizing and maintaining healthy cartilage, boosting their energy production.

“This perform not only highlights the potential off-target effect of semaglutide as an effective drug to treat metabolic osteoarthritis,” the research team from China and the US wrote in their published paper, “but also reveals a weight loss-independent repair mechanism.”

How Semaglutide Impacts Cartilage Metabolism

Osteoarthritis, often linked to obesity, metabolic disorders, and inflammation, affects not only bone and cartilage but also the synovium – the lubricating membrane lining joints. Semaglutide, a GLP-1 receptor agonist, mimics a natural hormone that stimulates insulin release and suppresses appetite.

The research pinpointed a crucial biological pathway altered by semaglutide: the “GLP-1R-AMPK-PFKFB3 axis.” This cascade of compounds influences how cells produce energy. In osteoarthritis-affected mice, semaglutide shifted the preferred metabolic pathway for cartilage cells (chondrocytes) from glycolysis – a less efficient, oxygen-independent process – to oxidative phosphorylation (OXPHOS), which generates significantly more energy.

Chondrocytes rely on glycolysis when stressed, but OXPHOS provides a more sustainable energy source for cartilage repair and maintenance. By promoting OXPHOS, semaglutide appears to enhance chondrocyte function and survival.

Human Trial Results: Pain Reduction and Cartilage Growth

A randomized human trial involving 20 participants aged 50-75 with obesity and osteoarthritis demonstrated promising results. Participants receiving both hyaluronic acid (HA) and semaglutide experienced lower osteoarthritis pain scores and improved knee function compared to those receiving HA alone. MRI analysis revealed thicker cartilage and evidence of cartilage growth in weight-bearing areas of the knee.

Implications for Global Health

With osteoarthritis affecting around 600 million people worldwide and projected to reach one billion by 2050 ScienceAlert, these findings have significant implications. The potential for a treatment that targets the underlying metabolic issues of osteoarthritis, rather than simply managing symptoms, offers hope for a more effective long-term solution.

Vital Considerations and Future Research

While the research is encouraging, experts caution against overoptimism. Mouse studies don’t always translate directly to human outcomes, and semaglutide use carries potential side effects. Further clinical trials are needed to validate these findings and determine the long-term efficacy and safety of semaglutide as an osteoarthritis treatment.

“The protective effects of semaglutide on the human knee joint should be interpreted with caution and require further validation by clinical trials,” the researchers conclude Cell Metabolism.

About the author: Dr Natalie Singh - Health Editor

Board‑certified internal‑medicine physician and MPH. Natalie authored peer‑reviewed studies on infectious disease and served as medical editor. “Dr. Natalie Singh delivers evidence‑based health news, medical breakthroughs, and expert wellness guidance.”